SCHEMBL721692

SCHEMBL721692

CCCCOC(=O)C(N)CCCCCN

nearest known ligand 0.54

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
GNAI3 P08754 1/20 0.54
GNAO1 P09471 1/20 0.54
GNAI1 P63096 1/20 0.54
GSR P00390 1/20 0.48
TLR2 O60603 2/20 0.48
NOD1 Q9Y239 2/20 0.48
DPP8 Q6V1X1 2/20 0.47
DPP9 Q86TI2 2/20 0.47
DPP7 Q9UHL4 2/20 0.47
CPB2 Q96IY4 1/20 0.45
ALDH1A1 P00352 1/20 0.42
RRM1 P23921 1/20 0.41
DPP4 P27487 1/20 0.41
DNM1 Q05193 3/20 0.40
GRIK1 P39086 1/20 0.40
GRIK2 Q13002 1/20 0.40
ATM Q13315 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL722145 1.00 GNAI3 (0.54) GNAI3GNAO1GNAI1GSRTLR2
SCHEMBL14935740 1.00 GNAI3 (0.54) GNAI3GNAO1GNAI1GSRTLR2
Hydrochloric Acid SCHEMBL6428766 0.98 GNAI3 (0.53) GNAI3GNAO1GNAI1GSRTLR2
SCHEMBL856465 0.98 GNAI3 (0.51) GNAI3GNAO1GNAI1GSRTLR2
SCHEMBL2494020 0.98 GNAI3 (0.51) GNAI3GNAO1GNAI1GSRTLR2
Hydrochloric Acid SCHEMBL9537364 0.97 GNAI3 (0.50) GNAI3GNAO1GNAI1GSRTLR2
Hydrochloric Acid SCHEMBL10580924 0.97 GNAI3 (0.50) GNAI3GNAO1GNAI1GSRTLR2
SCHEMBL7771135 0.95 GNAI3 (0.56) GNAI3GNAO1GNAI1GSRTLR2
SCHEMBL5267100 0.95 GNAI3 (0.56) GNAI3GNAO1GNAI1GSRTLR2
SCHEMBL10614116 0.95 GNAI3 (0.56) GNAI3GNAO1GNAI1GSRTLR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2014121819-A1 FOLATE FUNCTIONALIZED NANODIAMOND PARTICLES, METHOD FOR ITS PREPARATION AND THEIR USE Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. (DE) 2014-08-14 WO claimed
US-12605464-B2 Cyclohexane lipidoids for nucleic acid transfection and use thereof USTAV ORGANICKE CHEMIE A BIOCHEMIE AV CR, V.V.I. (CZ) 2026-04-21 US disclosed
US-20240335559-A1 CYCLOHEXANE LIPIDOIDS FOR NUCLEIC ACID TRANSFECTION AND USE THEREOF USTAV ORGANICKE CHEMIE A BIOCHEMIE AV CR, V.V.I. (CZ) 2024-10-10 US disclosed
EP-4373804-A1 CYCLOHEXANE LIPIDOIDS FOR NUCLEIC ACID TRANSFECTION AND USE THEREOF Ustav Organicke Chemie a Biochemie AV CR v.v.i. (CZ) 2024-05-29 EP disclosed
WO-2024089248-A1 RECOMBINANT ACTIVATION-ASSOCIATED SECRETED PROTEIN UNIVERSITEIT GENT (BE) 2024-05-02 WO disclosed
WO-2023001323-A1 CYCLOHEXANE LIPIDOIDS FOR NUCLEIC ACID TRANSFECTION AND USE THEREOF Ustav Organicke Chemie A Biochemie AV CR v.v.i. (CZ) 2023-01-26 WO disclosed
EP-4010368-A1 ANTI-NAMPT ANTIBODIES AND USES THEREOF Aqualung Therapeutics Corp. (US) 2022-06-15 EP disclosed
EP-3920969-A1 CONNEXIN 43 ANTIBODIES AND USE THEREOF Alamab Therapeutics, Inc. (US) 2021-12-15 EP disclosed
WO-2021134040-A2 ENHANCING EXPRESSION OF LINE-1 ENCODED ORF2P FOR CANCER THERAPEUTICS THE JOHNS HOPKINS UNIVERSITY (US) 2021-07-01 WO disclosed
EP-3830123-A1 ANTI-SIGLEC-5 ANTIBODIES AND METHODS OF USE THEREOF Alector LLC (US) 2021-06-09 EP disclosed
EP-1377830-A2 ARRAYS FOR DETERMINING BINDING OF BIOMOLECULES PEPSCAN SYSTEMS B.V. (NL) 2004-01-07 EP disclosed
EP-0854915-A4 CD23 PROCESSING ENZYME PREPARATION SMITHKLINE BEECHAM CORP (US) 2003-01-22 EP disclosed
WO-2002066984-A2 ARRAYS FOR DETERMINING BINDING OF BIOMOLECULES PEPSCAN SYSTEMS B.V. (NL) 2002-08-29 WO disclosed
US-6232089-B1 INHIBITED BY (4-(N-HYDROXYAMINO)-2-ISOBUTYL-3-(2-THIOPHENEMETHYL)-SUCCINYL) -PHENYLALANINE-N-METHYL AMIDE AND 1,10-PHENANTHROLINE SMITHKLINE BEECHAM CORPORATION 2001-05-15 US disclosed
EP-1097381-A1 METHOD FOR MANUFACTURING A CARRIER FOR CHEMICAL OR BIOCHEMICAL ASSAYS PEPSCAN SYSTEMS B.V. (NL) 2001-05-09 EP disclosed
WO-2000005584-A1 METHOD FOR MANUFACTURING A CARRIER FOR CHEMICAL OR BIOCHEMICAL ASSAYS PEPSCAN SYSTEMS B.V. (NL) 2000-02-03 WO disclosed
WO-2000005583-A1 PREPARATION CARRIER AND METHOD FOR ITS MANUFACTURE STICHTING DIENST LANDBOUWKUNDIG ONDERZOEK (NL) 2000-02-03 WO disclosed
EP-0854915-A1 CD23 PROCESSING ENZYME PREPARATION SMITHKLINE BEECHAM CORPORATION (US) 1998-07-29 EP disclosed
WO-1997013848-A1 CD23 PROCESSING ENZYME PREPARATION SMITHKLINE BEECHAM CORPORATION (US) 1997-04-17 WO disclosed
WO-1996035686-A1 TRYPTAMINE DERIVATIVES, PREPARATION THEREOF AND MEDICAMENTS CONTAINING THEM RHONE-POULENC RORER S.A. (FR) 1996-11-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240335559-A1 CYCLOHEXANE LIPIDOIDS FOR NUCLEIC ACID TRANSFECTION AND USE THEREOF SGMS2, NR1H3, SGMS1 GNAI3 2026/4885GNAO1 1147/4885GNAI1 2762/4885
US-12605464-B2 Cyclohexane lipidoids for nucleic acid transfection and use thereof NR1H2, NPC1, NR1H3 GNAI3 2050/4885GNAO1 904/4885GNAI1 2131/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.